Scarinci, Fabio http://orcid.org/0000-0001-5444-4377
Cacciamani, Andrea
Ripandelli, Guido
Parravano, Mariacristina http://orcid.org/0000-0002-2223-7311
Article History
Received: 14 January 2022
Accepted: 1 July 2022
First Online: 14 July 2022
Declarations
:
: Not applicable.
: Written informed consent to publish this information was obtained from study participant.
: Scarinci, Cacciamani and Ripandelli report no proprietary or financial interest to disclose.Parravano reports personal fees from Allergan, from Bayer, and from Novartis outside the submitted work. The remaining authors declare that they have no competing interests.